Skip to main content
SpringerLink
Log in

Management of Skin Cancers in Solid Organ Transplant Recipients

  • Chapter
  • First Online:
Skin Cancer Management

  • 476 Accesses

Abstract

Advances in immunosuppressive therapy and an increasing number of organ transplants have led to increased survival and an enlarging population of solid organ transplant recipients in the United States. However, with the immunosuppression necessitated to prevent graft failure, these patients are at an elevated risk of developing skin cancer. The risk of cutaneous squamous cell carcinoma (cSCC) in particular is significantly higher in organ transplant recipients, estimated at 100×, and often follows a more aggressive course. Appropriate and timely management is crucial involving routine skin cancer screening, surgical management of malignancy, consideration of chemoprophylaxis and prevention, and modulation of immunosuppressive therapy in these patients to decrease morbidity and mortality from cutaneous malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. United Network for Organ Sharing. Organ procurement and transplantation network. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/2018 [updated 11/30/2018; cited 2018 12/30/2018].

  2. Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252–9. [PMID: 25629390].

    PubMed  Google Scholar 

  3. Garrett GL, Blanc PD, Boscardin J, Lloyd AA, Ahmed RL, Anthony T, et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303. [PMID: 28097368].

    PubMed  Google Scholar 

  4. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1–17; quiz 8–20. [PMID: 12077575].

    PubMed  Google Scholar 

  5. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23(2):101–13. [PMID: 10945373].

    CAS  PubMed  Google Scholar 

  6. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91. [PMID: 12711744].

    PubMed  Google Scholar 

  7. Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatol Clin. 2011;29(2):231–41, ix. [PMID: 21421148].

    CAS  PubMed  Google Scholar 

  8. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years’ experience at a single centre. Transplant Proc. 1997;29(1–2):828–30. [PMID: 9123544].

    CAS  PubMed  Google Scholar 

  9. Edwards NM, Rajasinghe HA, John R, Chen JM, Itescu S, Mancini DM. Cardiac transplantation in over 1000 patients: a single institution experience from Columbia University. Clin Transpl. 1999:249–61. [PMID: 11038644].

    Google Scholar 

  10. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40(2 Pt 1):177–86. [PMID: 10025742].

    CAS  PubMed  Google Scholar 

  11. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol. 2001;27(4):409–13. [PMID: 11417989].

    CAS  PubMed  Google Scholar 

  12. O’Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–61. [PMID: 21763561].

    PubMed  Google Scholar 

  13. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143(3):513–9. [PMID: 10971322].

    CAS  PubMed  Google Scholar 

  14. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, et al.; group E-H-U-C. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol. 2007;127(7):1647–56. [PMID: 17380113].

    Google Scholar 

  15. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis. 2002;15(2):101–14. [PMID: 11964909].

    PubMed  Google Scholar 

  16. Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68(11):1717–21. [PMID: 10609948].

    CAS  PubMed  Google Scholar 

  17. Clarke CA, Robbins HA, Tatalovich Z, Lynch CF, Pawlish KS, Finch JL, et al. Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2). [PMID: 25575645].

    Google Scholar 

  18. Penn I. Malignancies associated with renal transplantation. Urology. 1977;10(1 Suppl):57–63. [PMID: 329521].

    CAS  PubMed  Google Scholar 

  19. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104(9):1962–7. [PMID: 16187269].

    PubMed  Google Scholar 

  20. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006;154(3):472–7. [PMID: 16445778].

    PubMed  Google Scholar 

  21. Katalinic A, Eisemann N, Waldmann A. Skin cancer screening in Germany. Documenting melanoma incidence and mortality from 2008 to 2013. Dtsch Arztebl Int. 2015;112(38):629–34. [PMID: 26429634].

    PubMed  PubMed Central  Google Scholar 

  22. Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-Garcia C, Rodriguez-Pazos L, Pastushenko I, et al. Skin cancer incidence and mortality in Spain: a systematic review and meta-analysis. Actas Dermosifiliogr. 2016;107(4):318–28. [PMID: 26852370].

    CAS  PubMed  Google Scholar 

  23. Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, Quan KK, Keeling JH, et al. Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol. 2008;59(3):405–17. [PMID: 18556089].

    PubMed  Google Scholar 

  24. Goldman GD. Squamous cell cancer: a practical approach. Semin Cutan Med Surg. 1998;17(2):80–95. [PMID: 9669602].

    CAS  PubMed  Google Scholar 

  25. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996;1(2):136–42. [PMID: 9627707].

    CAS  PubMed  Google Scholar 

  26. Athar M, Walsh SB, Kopelovich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys. 2011;508(2):159–63. [PMID: 21232524].

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247–59. [PMID: 17627060].

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Bouwes Bavinck JN, Feltkamp M, Struijk L, ter Schegget J. Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Investig Dermatol Symp Proc. 2001;6(3):207–11. [PMID: 11924829].

    CAS  PubMed  Google Scholar 

  29. Khavari TA, Rinn J. Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia. Cell Cycle. 2007;6(23):2928–31. [PMID: 18000402].

    CAS  PubMed  Google Scholar 

  30. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003;421(6923):639–43. [PMID: 12571598].

    CAS  PubMed  Google Scholar 

  31. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126(4):869–81. [PMID: 16470182].

    CAS  PubMed  Google Scholar 

  32. Mitsui H, Suarez-Farinas M, Gulati N, Shah KR, Cannizzaro MV, Coats I, Felsen D, Krueger JG, Carucci JA. Gene expression profiling of the leading edge of cutaneous squamous cell carcinoma: IL-24-driven MMP-7. J Invest Dermatol. 2014;134(5):1418–27. [PMID: 24270662].

    CAS  PubMed  Google Scholar 

  33. Zhang S, Fujita H, Mitsui H, Yanofsky VR, Fuentes-Duculan J, Pettersen JS, et al. Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One. 2013;8(5):e62154. [PMID: 23667456].

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Abikhair M, Mitsui H, Yanofsky V, Roudiani N, Ovits C, Bryan T, et al. Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. JCI Insight. 2016;1(8):e86434. [PMID: 27699266].

    PubMed  PubMed Central  Google Scholar 

  35. Abikhair Burgo M, Roudiani N, Chen J, Santana AL, Doudican N, Proby C, et al. Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. JCI Insight. 2018;3(17). [PMID: 30185657].

    Google Scholar 

  36. Abikhair M, Roudiani N, Mitsui H, Krueger JG, Pavlick A, Lee J, et al. MAGEA3 expression in cutaneous squamous cell carcinoma is associated with advanced tumor stage and poor prognosis. J Invest Dermatol. 2017;137(3):775–8. [PMID: 27826009].

    CAS  PubMed  Google Scholar 

  37. Lai EC. Notch signaling: control of cell communication and cell fate. Development. 2004;131(5):965–73. [PMID: 14973298].

    CAS  PubMed  Google Scholar 

  38. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–21. [PMID: 12590261].

    CAS  PubMed  Google Scholar 

  39. Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006;66(15):7438–44. [PMID: 16885339].

    CAS  PubMed  Google Scholar 

  40. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol. 1983;35(1):15–8. [PMID: 6131958].

    CAS  PubMed  Google Scholar 

  41. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30(4):358–63. [PMID: 2341582].

    CAS  PubMed  Google Scholar 

  42. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–4. [PMID: 16166520].

    PubMed  PubMed Central  Google Scholar 

  43. Borel JF, Di Padova F, Mason J, Quesniaux V, Ryffel B, Wenger R. Pharmacology of cyclosporine (sandimmune). I. Introduction. Pharmacol Rev. 1990;41(3):239–42. [PMID: 2185487].

    CAS  PubMed  Google Scholar 

  44. Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, Grizzle WE, et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinog. 2011;50(7):516–27. [PMID: 21308804].

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4. [PMID: 10028970].

    CAS  PubMed  Google Scholar 

  46. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion. 2010;10(2):94–101. [PMID: 19836469].

    CAS  PubMed  Google Scholar 

  47. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg. 2004;30(4 Pt 2):628–33. [PMID: 15061847].

    PubMed  Google Scholar 

  48. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39. [PMID: 22830463].

    CAS  PubMed  Google Scholar 

  49. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679. [PMID: 25422259].

    PubMed  PubMed Central  Google Scholar 

  50. Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. JAMA Dermatol. 2016;152(5):533–40. [PMID: 26792250].

    PubMed  Google Scholar 

  51. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12(5):1146–56. [PMID: 22420843].

    CAS  PubMed  Google Scholar 

  52. Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014;58(7):997–1002. [PMID: 24363331].

    PubMed  Google Scholar 

  53. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm622251.htm: U.S. Food & Drug Administration; 2018 [cited 2018].

  54. Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, Weaver AL, Transplant-Skin CC. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol. 2003;139(3):301–6. [PMID: 12622621].

    PubMed  Google Scholar 

  55. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26(6):976–90. [PMID: 1607418].

    CAS  PubMed  Google Scholar 

  56. Lanz J, Bouwes Bavinck JN, Westhuis M, Quint KD, Harwood CA, Nasir S, et al. Aggressive squamous cell carcinoma in organ transplant recipients. JAMA Dermatol. 2018. [PMID: 30516812].

    Google Scholar 

  57. Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006;13(7):902–9. [PMID: 16788750].

    PubMed  Google Scholar 

  58. Stasko T, Brown MD, Carucci JA, Euvrard S, Johnson TM, Sengelmann RD, et al.; International Transplant-Skin Cancer C, European Skin Care in Organ Transplant Patients N. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):642–50. [PMID: 15061849].

    Google Scholar 

  59. Euvrard S, Kanitakis J, Pouteil-Noble C, Disant F, Dureau G, Finaz de Villaine J, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc. 1995;27(2):1767–8. [PMID: 7725494].

    CAS  PubMed  Google Scholar 

  60. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients--where do we stand today? Am J Transplant. 2008;8(11):2192–8. [PMID: 18782290].

    CAS  PubMed  Google Scholar 

  61. Bavinck JN, De Boer A, Vermeer BJ, Hartevelt MM, van der Woude FJ, Claas FH, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol. 1993;129(3):242–9. [PMID: 8286220].

    CAS  PubMed  Google Scholar 

  62. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995;346(8972):403–6. [PMID: 7623570].

    CAS  PubMed  Google Scholar 

  63. Glover MT, Niranjan N, Kwan JT, Leigh IM. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg. 1994;47(2):86–9. [PMID: 8149064].

    CAS  PubMed  Google Scholar 

  64. De Graaf YG, Euvrard S, Bouwes Bavinck JN. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):656–61. [PMID: 15061851].

    PubMed  Google Scholar 

  65. Carucci JA, Martinez JC, Zeitouni NC, Christenson L, Coldiron B, Zweibel S, Otley CC. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg. 2004;30(4 Pt 2):651–5. [PMID: 15061850].

    PubMed  Google Scholar 

  66. Ma JH, Wu A, Veness M, Estall V, Hong A, Borg M, James C, et al. In-transit metastasis from squamous cell carcinoma. Dermatol Surg. 2016;42(11):1285–92. [PMID: 27598442].

    CAS  PubMed  Google Scholar 

  67. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541–7. [PMID: 23677079].

    PubMed  Google Scholar 

  68. Brantsch KD, Meisner C, Schonfisch B, Trilling B, Wehner-Caroli J, Rocken M, Breuninger H. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20. [PMID: 18617440].

    PubMed  Google Scholar 

  69. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811–5. [PMID: 22592943].

    PubMed  Google Scholar 

  70. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–66. [PMID: 23375456].

    PubMed  Google Scholar 

  71. Mertz KD, Proske D, Kettelhack N, Kegel C, Keusch G, Schwarz A, et al. Basal cell carcinoma in a series of renal transplant recipients: epidemiology and clinicopathologic features. Int J Dermatol. 2010;49(4):385–9. [PMID: 20465691].

    PubMed  Google Scholar 

  72. Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. J Am Acad Dermatol. 2016;75(1):106–12. [PMID: 27067869].

    PubMed  Google Scholar 

  73. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis. 2000;36(1):167–76. [PMID: 10873887].

    CAS  PubMed  Google Scholar 

  74. Jiyad Z, Marquart L, O’Rourke P, Green AC. The natural history of actinic keratoses in organ transplant recipients. J Am Acad Dermatol. 2017;76(1):162–4. [PMID: 27986142].

    PubMed  Google Scholar 

  75. Ad Hoc Task F, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50. [PMID: 22959232].

    Google Scholar 

  76. Wang A, Chan AW, Aasi S, Lee C, Krathen M. Skin cancer prevention and treatment in solid organ transplant patients: a survey of the international transplant skin cancer collaborative. Dermatol Surg. 2016;42(5):682–3. [PMID: 27045747].

    CAS  PubMed  Google Scholar 

  77. Ingham AI, Weightman W. The efficacy and safety of topical 5% 5-fluorouracil in renal transplant recipients for the treatment of actinic keratoses. Australas J Dermatol. 2014;55(3):204–8. [PMID: 24627952].

    PubMed  Google Scholar 

  78. Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106–16. [PMID: 27869649].

    PubMed  Google Scholar 

  79. Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, Stockfleth E. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006;155(2):451–4. [PMID: 16882188].

    CAS  PubMed  Google Scholar 

  80. Trakatelli M, Katsanos G, Ulrich C, Kalabalikis D, Sotiriadis D, Stockfleth E. Efforts to counteract locally the effects of systemic immunosuppression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. Int J Immunopathol Pharmacol. 2010;23(2):387–96. [PMID: 20646334].

    CAS  PubMed  Google Scholar 

  81. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157 Suppl 2:25–31. [PMID: 18067628].

    CAS  PubMed  Google Scholar 

  82. Santos-Juanes J, Esteve A, Mas-Vidal A, Coto-Segura P, Salgueiro E, Gomez E, Galache OC. Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: review of the literature on side effects of imiquimod. Dermatology. 2011;222(2):109–12. [PMID: 21304243].

    CAS  PubMed  Google Scholar 

  83. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–61. [PMID: 29332705].

    PubMed  Google Scholar 

  84. Ulrich C, Hackethal M, Ulrich M, Howorka A, Forschner T, Sterry W, Stockfleth E. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol. 2007;156 Suppl 3:40–2. [PMID: 17488405].

    CAS  PubMed  Google Scholar 

  85. Perrett CM, McGregor JM, Warwick J, Karran P, Leigh IM, Proby CM, Harwood CA. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156(2):320–8. [PMID: 17223873].

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, Baldan N, Alaibac M, Marchini F. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc. 2007;39(6):1847–50. [PMID: 17692630].

    CAS  PubMed  Google Scholar 

  87. Togsverd-Bo K, Omland SH, Wulf HC, Sorensen SS, Haedersdal M. Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. Am J Transplant. 2015;15(11):2986–90. [PMID: 26018207].

    CAS  PubMed  Google Scholar 

  88. Lens M, Medenica L. Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother. 2008;9(8):1363–74. [PMID: 18473710].

    CAS  PubMed  Google Scholar 

  89. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, Vermeer BJ. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933–8. [PMID: 7636533].

    CAS  PubMed  Google Scholar 

  90. McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol. 1999;140(4):656–60. [PMID: 10233316].

    CAS  PubMed  Google Scholar 

  91. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. 2005;141(4):456–64. [PMID: 15837863].

    CAS  PubMed  Google Scholar 

  92. Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013;39(4):634–45. [PMID: 23379978].

    CAS  PubMed  Google Scholar 

  93. Wollina U, Hansel G, Koch A, Kostler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005;131(5):300–4. [PMID: 15619125].

    CAS  PubMed  Google Scholar 

  94. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Lee PK, Dudek AZ. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transpl. 2011;25(4):541–8. [PMID: 21050273].

    CAS  Google Scholar 

  95. Ratz Bravo AE, Hofer S, Krahenbuhl S, Ludwig C. Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol. 2009;48(4):631–3. [PMID: 19165642].

    CAS  PubMed  Google Scholar 

  96. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–26. [PMID: 26488693].

    CAS  PubMed  Google Scholar 

  97. Chen AC, Martin AJ, Dalziell RA, McKenzie CA, Lowe PM, Eris JM, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br J Dermatol. 2016;175(5):1073–5. [PMID: 27061568].

    CAS  PubMed  Google Scholar 

  98. Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study. Eur J Dermatol. 2017;27(4):382–5. [PMID: 28468736].

    CAS  PubMed  Google Scholar 

  99. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. European Nicotinamide Diabetes Intervention Trial G. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43(11):1337–45. [PMID: 11126400].

    CAS  PubMed  Google Scholar 

  100. Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol. 2017;76(2):217–25. [PMID: 27707594].

    PubMed  Google Scholar 

  101. Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150(1):19–24. [PMID: 24226651].

    PubMed  Google Scholar 

  102. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2. [PMID: 2004320].

    CAS  PubMed  Google Scholar 

  103. Shao XH, Xu YS, Zhang XQ, Li WF. Evidence based analysis of Cisplatin for treating patients with cutaneous squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(22):9813–5. [PMID: 25520110].

    PubMed  Google Scholar 

  104. Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303. [PMID: 28259107].

    PubMed  Google Scholar 

  105. Otley CC, Berg D, Ulrich C, Stasko T, Murphy GM, Salasche SJ, et al.; Reduction Of Immunosuppression Task Force Of The International Transplant Skin Cancer C, The Skin Care In Organ Transplant Patients E. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol. 2006;154(3):395–400. [PMID: 16445766].

    Google Scholar 

  106. Colegio OR, Hanlon A, Olasz EB, Carucci JA. Sirolimus reduces cutaneous squamous cell carcinomas in transplantation recipients. J Clin Oncol. 2013;31(26):3297–8. [PMID: 23918945].

    PubMed  Google Scholar 

  107. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, Proby CM, Wolterbeek R, Bouwes Bavinck JN, de Fijter JW. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317–23. [PMID: 23358973].

    CAS  PubMed  Google Scholar 

  108. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl. 2004;18(4):446–9. [PMID: 15233824].

    Google Scholar 

  109. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26. [PMID: 21810686].

    CAS  PubMed  Google Scholar 

  110. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014;25(5):424–7. [PMID: 23167307].

    CAS  PubMed  Google Scholar 

  111. Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26(12):1340–4. [PMID: 18096489].

    PubMed  Google Scholar 

  112. Kean LS, Turka LA, Blazar BR. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev. 2017;276(1):192–212. [PMID: 28258702].

    CAS  PubMed  PubMed Central  Google Scholar 

  113. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209. [PMID: 27085692].

    CAS  PubMed  Google Scholar 

  114. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25. [PMID: 27084345].

    CAS  PubMed  Google Scholar 

  115. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135–7. [PMID: 26951628].

    CAS  PubMed  Google Scholar 

  116. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332–3. [PMID: 26752406].

    CAS  PubMed  Google Scholar 

  117. Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896–8. [PMID: 26962927].

    PubMed  PubMed Central  Google Scholar 

  118. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32(19):e69–71. [PMID: 24493726].

    PubMed  PubMed Central  Google Scholar 

  119. Barnett R, Barta VS, Jhaveri KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med. 2017;376(2):191–2. [PMID: 28076715].

    PubMed  Google Scholar 

  120. Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol. 2016;43(8):663–70. [PMID: 27153517].

    PubMed  Google Scholar 

  121. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51. [PMID: 29863979].

    CAS  PubMed  Google Scholar 

  122. Cusack CA, Nijhawan R, Miller B, Henien M, Malat G, Doyle A, Abdelmalek M. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient. JAMA Dermatol. 2015;151(1):70–2. [PMID: 25337679].

    PubMed  Google Scholar 

  123. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(4):450–73. [PMID: 27059193].

    Google Scholar 

  124. Zwald FO, Christenson LJ, Billingsley EM, Zeitouni NC, Ratner D, Bordeaux J, et al.; Melanoma Working Group of The International Transplant Skin Cancer C, Skin Care in Organ Transplant Patients E. Melanoma in solid organ transplant recipients. Am J Transplant. 2010;10(5):1297–304. [PMID: 20353465].

    Google Scholar 

  125. Christenson LJ, Geusau A, Ferrandiz C, Brown CD, Ulrich C, Stockfleth E, et al. Specialty clinics for the dermatologic care of solid-organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):598–603. [PMID: 15061842].

    PubMed  Google Scholar 

  126. Clowers-Webb HE, Christenson LJ, Phillips PK, Roenigk RK, Nguyen TH, Weaver AL, Otley CC. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs standard education. Arch Dermatol. 2006;142(6):712–8. [PMID: 16785373].

    PubMed  Google Scholar 

  127. Ulrich C, Jurgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161 Suppl 3:78–84. [PMID: 19775361].

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, The Ronald O. Perelman Department of Dermatology, New York University, New York, NY, USA

    Margo Lederhandler, Mary L. Stevenson & John A. Carucci

Authors
  1. Margo Lederhandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary L. Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John A. Carucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John A. Carucci .

Editor information

Editors and Affiliations

  1. Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Deborah F. MacFarlane

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lederhandler, M., Stevenson, M.L., Carucci, J.A. (2021). Management of Skin Cancers in Solid Organ Transplant Recipients. In: MacFarlane, D.F. (eds) Skin Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-030-50593-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-50593-6_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-50592-9

  • Online ISBN: 978-3-030-50593-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation